» Articles » PMID: 28255022

Molecular Features of Early Onset Adult Myelodysplastic Syndrome

Abstract

Myelodysplastic syndromes are typically diseases of older adults. Patients in whom the onset is early may have distinct molecular and clinical features or reflect a demographic continuum. The identification of differences between "early onset" patients and those diagnosed at a traditional age has the potential to advance understanding of the pathogenesis of myelodysplasia and may lead to formation of distinct morphological subcategories. We studied a cohort of 634 patients with various subcategories of myelodysplastic syndrome and secondary acute myeloid leukemia, stratifying them based on age at presentation and clinical parameters. We then characterized molecular abnormalities detected by next-generation deep sequencing of 60 genes that are commonly mutated in myeloid malignancies. The number of mutations increased linearly with age and on average, patients >50 years of age had more mutations. , , and were more commonly mutated in patients >50 years old compared to patients ≤50 years old. In general, patients >50 years of age also had more mutations in spliceosomal, epigenetic modifier, and RAS gene families. Although there are age-related differences in molecular features among patients with myelodysplasia, most notably in the incidence of mutations, our results suggest that patients ≤50 years old belong to a disease continuum with a distinct pattern of early onset ancestral events.

Citing Articles

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.

Testa U, Castelli G, Pelosi E Mediterr J Hematol Infect Dis. 2023; 15(1):e2023038.

PMID: 37435040 PMC: 10332352. DOI: 10.4084/MJHID.2023.038.


Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.

Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A Nat Commun. 2023; 14(1):3153.

PMID: 37258544 PMC: 10232425. DOI: 10.1038/s41467-023-38113-4.


Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.

Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A Res Sq. 2023; .

PMID: 37066269 PMC: 10104200. DOI: 10.21203/rs.3.rs-2773498/v1.


Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes.

Nagata Y, Zhao R, Awada H, Kerr C, Mirzaev I, Kongkiatkamon S Blood. 2020; 136(20):2249-2262.

PMID: 32961553 PMC: 7702479. DOI: 10.1182/blood.2020005488.


Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.

Guan Y, Greenberg E, Hasipek M, Chen S, Liu X, Kerr C Commun Biol. 2020; 3(1):493.

PMID: 32895473 PMC: 7477582. DOI: 10.1038/s42003-020-01220-9.


References
1.
Yates A, Akanni W, Amode M, Barrell D, Billis K, Carvalho-Silva D . Ensembl 2016. Nucleic Acids Res. 2015; 44(D1):D710-6. PMC: 4702834. DOI: 10.1093/nar/gkv1157. View

2.
Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

3.
Burgstaller S, Wiesinger P, Stauder R . Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. Drugs Aging. 2015; 32(11):891-905. DOI: 10.1007/s40266-015-0312-7. View

4.
Silva P, Neumann M, Schroeder M, Vosberg S, Schlee C, Isaakidis K . Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia. 2017; 31(7):1640-1644. DOI: 10.1038/leu.2017.109. View

5.
Churpek J, Pyrtel K, Kanchi K, Shao J, Koboldt D, Miller C . Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015; 126(22):2484-90. PMC: 4661171. DOI: 10.1182/blood-2015-04-641100. View